How do the two approaches to treating high-risk smoldering multiple myeloma (HRSMM) patients differ?

 

In this week’s video, Dr. Brian G.M. Durie compares two trials that treat high-risk smoldering multiple myeloma — the CESAR trial and the CENTAURUS trial.

BOTTOM LINE:

The IMF’s Black Swan Research Initiative is excited about the CESAR trial and will conduct future trials in hopes of achieving a cure for myeloma.

If you have a question that you’d like to suggest for a future episode of Ask Dr. Durie, please submit it to [email protected]

To reach the IMF InfoLine Coordinators, please call 800.452.2873 or email them at [email protected]


Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

Video
IMF TV Blog Category
Old Id
785

Source URL: https://www.myeloma.org/videos/how-do-two-approaches-treating-high-risk-smoldering-multiple-myeloma-hrsmm-patients-differ